Random Whole Body Vibration over 5 Weeks Leads to Effects Similar to Placebo: A Controlled Study in Parkinson’s Disease

Table 1

Anthropometric and clinical data of participants.

	Group	Sex	Age (a)	Height (m)	Weight (kg)	Body mass index (kg/m^2)	Arm length (m)	Leg length (m)	Foot length (m)	Disease duration (a)	Hoehn and Yahr (stage)	L-Dopa equivalent dose (mg/day)
1	Experimental	m	74	1.83	80.0	23.9	0.87	0.96	0.30	8	2.0	0
2	Experimental	m	76	1.75	86.9	28.4	0.86	0.89	0.27	5	2.5	600
3	Experimental	f	75	1.62	66.3	25.3	0.78	0.78	0.26	4	3.0	0
4	Experimental	m	70	1.69	73.8	25.8	0.76	0.82	0.25	10	3.0	400
5	Experimental	m	66	1.75	100.1	32.7	0.79	0.85	0.28	15	2.5	700
6	Experimental	f	68	1.56	48.1	19.8	0.75	0.85	0.27	10	3.0	700
7	Experimental	m	76	1.71	87.7	30.0	0.82	0.84	0.27	2	3.0	112.5
8	Experimental	m	66	1.68	68.2	24.2	0.88	0.84	0.27	7	2.5	400
Mean (SD)			71.4 (4.4)	1.70 (0.08)	76.4 (16.1)	26.3 (4.0)	0.81 (0.05)	0.85 (0.05)	0.27 (0.02)	7.6 (4.1)	2.7 (0.37)	364 (296)
9	Placebo	m	70	1.78	70.5	22.3	0.83	0.90	0.27	3	2.5	150
10	Placebo	f	73	1.56	78.1	32.1	0.73	0.76	0.24	5	2.0	700
11	Placebo	m	69	1.62	75.0	28.6	0.76	0.79	0.27	4	2.0	75
12	Placebo	m	73	1.71	79.2	27.1	0.79	0.84	0.28	20	2.5	600
13	Placebo	f	67	1.54	47.8	20.2	0.74	0.79	0.25	2	3.0	150
14	Placebo	m	74	1.69	60.3	21.1	0.79	0.91	0.27	4	3.0	400
15	Placebo	m	60	1.65	63.9	23.5	0.86	0.88	0.26	8	2.5	600
16	Placebo	m	62	1.86	85.2	24.6	0.87	0.95	0.30	17	3.0	925
17	Placebo	m	66	1.68	68.2	24.2	0.88	0.84	0.27	7	2.5	400
Mean (SD)			68.2 (4.9)	1.68 (0.10)	69.8 (11.4)	24.9 (3.8)	0.81 (0.06)	0.85 (0.06)	0.26 (0.02)	7.8 (6.4)	2.6 (0.39)	444 (287)